Study of Obeldesivir to Treat Children With Respiratory Syncytial Virus (RSV) Infection
A Phase 2, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Obeldesivir in Participants From Birth to < 5 Years of Age With Respiratory Syncytial Virus (RSV) Infection
Sponsor: Gilead Sciences
Terminated
Study was terminated by Sponsor; the decision was not due to any safety findings.
Other terminated trials from Gilead Sciences
Other RSV Infection trials with similar outcome
Listed as NCT06784973, this PHASE2 trial focuses on RSV Infection and remains terminated or withdrawn. Sponsored by Gilead Sciences, it has been updated 7 times since 2025, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .